Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer is a research paper published in Cancers (2025). On theSindex it has a DataRank of 0. It has been cited 14 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Department of Defense
Grant: CA2220729
Department of Defense
Grant: OC190352
Department of Defense
Grant: 13461923
Department of Defense
Grant: R01 5CA99908-22
Department of Defense
Grant: P50CA265793
Department of Defense
Grant: P30CA118100
Department of Defense
Grant: K22 CA263783
Department of Defense
Grant: P30 CA086862
NCI NIH HHS
Grant: R01 CA099908
NIH and the Department of Defense Congressionally Directed Medical Research Program
Grant: NIH 2R01CA 99908-16A1, "Targeted Therapy for Endometrial Cancer", 2/15/2019-6/31/2024, K. Leslie, PI. OC190352 "Converting Mutant p53 into an Actionable Target for the Treatment of Ovarian Cancer", Department of Defense (DoD), 2020-09/30/2024, K. Leslie,
NCI NIH HHS
Grant: P01 CA278735
National Institutes of Health
Grant: 7R01CA099908-19
Targeted Therapy for Endometrial Cancer
National Institutes of Health
Grant: 5K22CA263783-02
Attacking aggressive p53 mutants in gynecologic cancer
National Institutes of Health
Grant: 1P30CA086862-01
Core--Clinical trials support group
National Institutes of Health
Grant: 5P30CA118100-05
CANCER CENTER RESEARCH ADMINISTRATION
FWCI
10.82
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords